Does the CYP3A5*3 polymorphism affect in vivo drug elimination?

Pharmacogenetics. 2003 Oct;13(10):585-7. doi: 10.1097/00008571-200310000-00001.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Anti-Anxiety Agents / pharmacokinetics*
  • Cytochrome P-450 CYP3A
  • Cytochrome P-450 Enzyme System / genetics*
  • Genotype
  • Humans
  • Metabolic Clearance Rate
  • Midazolam / pharmacokinetics*
  • Phenotype
  • Polymorphism, Genetic*

Substances

  • Anti-Anxiety Agents
  • Cytochrome P-450 Enzyme System
  • CYP3A protein, human
  • CYP3A5 protein, human
  • Cytochrome P-450 CYP3A
  • Midazolam